BioCentury
ARTICLE | Clinical News

Betalutin: Additional Phase I/II data

September 12, 2016 7:00 AM UTC

Data from 8 patients with relapsed CD37+ indolent B cell NHL in the open-label, dose-escalation, European Phase I/II LYMRIT-37-01 trial showed that pre-dosing with a 40 mg dose of unlabeled lilotomab ...